The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients

When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients

February 15, 2017 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Often, a thorough medical history and physical examination combined with a high-resolution CT scan can answer the diagnostic question, said Brett Elicker, MD, associate professor of radiology at UCSF. The high-resolution CT scan remains the modality of choice for detecting ILD in CTD and guiding future workups.

You Might Also Like
  • Tackle Tricky Lung Complications in Connective Tissue Disease
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)
Explore This Issue
February 2017

Speakers at the conference also presented a range of viewpoints on the risks and benefits of performing diagnostic lung biopsies in patients with CTD-ILD. “In the current era, we often do not perform a lung biopsy unless it’s going to impact treatment,” Dr. Fischer said. “Where I do recommend them is for idiopathic patients where you’re not clear on the etiology or in CTD patients with compelling concerns for an alternative cause, such as hypersensitivity pneumonitis.”

Harold Collard, MD

Harold Collard, MD

“I view surgical lung biopsy as a low-risk intervention—but not no risk,” added Harold Collard, MD, director of the ILD program at UCSF. He also highlighted alternate approaches to traditional video-assisted thoracoscopic surgery, including transbronchial cryobiopsy, which allows harvesting of up to 1 cm samples of tissue endoscopically.2

There are few research-supported treatments for many of the conditions under the CTD-ILD umbrella, Dr. Fischer said. Rheumatologists may look to scleroderma with lung involvement as a model for the treatment of other CTDs, because more is known about it. “I’m a rheumatologist—we often treat our patients with corticosteroids. But these are not good for the long term. So we look for steroid-sparing agents, as with any other rheumatologic condition.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Rheumatologists also recommend immuno­suppressive treatments for CTD-ILD conditions. One of those is cyclophosphamide, Dr. Fischer said. “If I use it, I use it short term and intravenously.” Other common treatments include azathio­prine and mycophenolate mofetil, which has gained popularity as a potential glucocorticoid-sparing agent for the treatment of patients with a diverse spectrum of CTD-ILD.

Two drugs approved in recent years for the treatment of idiopathic pulmonary fibrosis, nintedanib, a tyrosine kinase inhibitor, and pirfenidone, an anti-fibrotic agent, are in various stages of clinical trial investigation for potential treatment of fibrotic ILD in CTD patients.

Non-Pharmaceutical Approaches

Jeffrey Golden, MD

Jeffrey Golden, MD

For lung conditions that often cannot be cured—only managed or stabilized—non-pharmacologic treatments are an important component of comprehensive ILD care, Dr. Collard said. “The suffering of these patients cannot be overestimated. But non-pharmacologic interventions can positively impact how they feel.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pulmonary rehabilitation is a comprehensive intervention, based on a thorough patient assessment, that incorporates exercise and conditioning, education and behavioral change. Support groups are valued by ILD patients because they feel they are not so alone, with support from others who understand what they are going through.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Education & Training, Meeting Reports Tagged With: Clinical, connective tissue disorder, Diagnosis, interstitial lung disorder, patient care, Research, Rheumatic Disease, rheumatologist, rheumatology, therapy, TreatmentIssue: February 2017

You Might Also Like:
  • Tackle Tricky Lung Complications in Connective Tissue Disease
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)
  • Summit on Connective Tissue Disease-Associated ILD Fosters Interdisciplinary Dialogue

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)